Looks like losses went down qt/qt by nearly half to (605,500). Cash on hand increased a bit. Loss per common share decreased by .01.
ADMD is going in the right direction. This is one quarter, I look forward to them building further positive momentum in the quarters to come. Increase in isotope sales and direction from the FDA after their initial review should be recognized this summer. In my opinion ADMD is still certainly a buy down here at this quite depressed share price.
The weak hands are being worked out of the shareholder pool and strong hands coming in like Brookline and longs like myself.